Glucose & Insulin Research
Tirzepatide research on glucose homeostasis, insulin secretion, and beta-cell function.
Glucose & Insulin Research
Tirzepatide's dual GIP/GLP-1 mechanism produces enhanced glycemic effects compared to single-receptor agonists.
Incretin Synergy
Both GIP and GLP-1 are incretin hormones secreted after meals to amplify insulin secretion. Together:
- Dual stimulation of insulin secretion from different receptor pathways
- More complete post-meal glucose control
- Greater first-phase insulin response
SURPASS Trial Glycemic Data
- SURPASS-2: Tirzepatide 15mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1mg
- SURPASS-3: 40.8% achieved HbA1c <5.7% (normal range)
- Significantly lower fasting and postprandial glucose vs comparators
Beta-Cell Preservation
Research suggests dual agonism may provide superior beta-cell preservation compared to GLP-1 agonism alone, potentially through GIP receptor-mediated anti-apoptotic pathways.
Research-Grade Glucose & Insulin Research
>98% purity, third-party tested. Free shipping on orders over $200.
Glucose & Insulin Research — Available Products
Research-grade compounds. >98% purity, CoA available on request.
Frequently Asked Questions
How does tirzepatide compare to semaglutide for glucose control?
SURPASS-2 showed tirzepatide 15mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1mg, demonstrating superior glycemic control from dual agonism.
Does tirzepatide cause hypoglycemia?
Both GIP and GLP-1 receptor agonism are glucose-dependent, meaning tirzepatide stimulates insulin only when blood glucose is elevated. Hypoglycemia risk is low without concurrent sulfonylurea or insulin use.
What is the incretin effect?
The incretin effect refers to the greater insulin response to oral vs. intravenous glucose due to incretin hormones (GIP and GLP-1) released from the gut after eating.
Research-Grade Glucose & Insulin Research
Third-party tested, >98% purity guaranteed. For legitimate scientific research.